Primary lung tumor in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding primary lung tumor

A primary lung tumor starts in the lung itself and is different from cancer that has spread to the lungs from somewhere else. A single resectable mass can have a very different outlook from multiple nodules or pleural disease. Pathology, chest lymph nodes and evidence of cancer elsewhere help define the situation.

What does the prognosis look like?

A solitary lung tumor that can be completely removed may allow meaningful long-term control. In one contemporary surgical study, the typical survival time was about 15 months for dogs without cancer in chest lymph nodes and about 5–6 months when nodes were positive; the small study could not prove that difference statistically. Multiple lesions, pleural disease and aggressive pathology also worsen the outlook.

What matters next

First establish whether this looks like one primary lung tumor or could be spread from another cancer. If it is solitary, the important questions are whether it can be removed and whether chest lymph nodes or the pleura are involved. Breathing difficulty or fluid around the lungs needs stabilization before elective cancer planning.

Where are you now?

There is one apparently resectable lung mass

Confirm that the lesion is likely a primary lung tumor rather than metastasis and use imaging to assess resectability and intrathoracic lymph nodes before surgery.

The lung mass was already removed

Review the exact histology, grade or differentiation when reported, surgical margins, and lymph-node status. Those findings help determine whether surveillance alone or additional systemic treatment is reasonable.

There are multiple lung nodules

Multiple nodules raise the possibility of metastatic disease from another primary cancer or multifocal lung disease. Do not apply surgery outcomes from a solitary primary mass until the diagnosis is secure.

The tumor is unresectable or metastatic

Systemic treatment, radiation for selected lesions, and symptom-directed care may all have roles. Breathing comfort and the actual pace of progression should stay central to the plan.

If you are waiting for oncology

Confirm that a lung mass is likely primary rather than metastatic from another cancer. For a solitary lesion, CT and surgical assessment can determine resectability and lymph-node involvement before the window for surgery closes.

Questions to ask your oncologist

Does this look like a primary lung tumor or metastasis from another site?
Is the lesion surgically resectable and are intrathoracic nodes suspicious?
If surgery is done, will lymph nodes be sampled and how will pathology affect follow-up treatment?

How the diagnosis may appear in the record

The central distinction is a primary lung tumor versus cancer metastatic to the lungs. For a removed primary tumor, keep the histologic type, differentiation or grade when reported, measured margins, lymph-node status, and any pleural involvement. Multiple nodules should not be assigned a primary-lung prognosis without establishing their origin.

Changes to watch for at home

Report increasing cough, faster breathing at rest, reduced stamina, appetite or weight loss, pain, or lameness. Labored breathing, blue or very pale gums, collapse, or inability to settle because of breathing is urgent.

How it is usually treated

For a solitary resectable primary lung tumor, surgical removal of the affected lung lobe is the usual treatment. Additional chemotherapy or another systemic treatment may be considered when pathology is high risk, lymph nodes are involved, the tumor cannot be removed completely or metastatic disease is present.

What can affect treatment choices

A solitary removable primary tumor is different from multifocal or metastatic lung disease. Lymph-node involvement, pathology and whether complete surgery is possible are especially important.

Tests that may matter

Chest CT is often the most useful test when surgery is being considered because it shows the primary mass, chest lymph nodes and additional nodules better than radiographs. Pathology after removal confirms tumor type and grade, and lymph-node sampling can add important staging information.

Treatment options available now

5 options currently in our catalog.

Check eligibility

Gilvetmab for primary pulmonary carcinoma in dogs

University of Missouri Veterinary Health Center · USA

Location

University of Missouri Veterinary Health Center, 900 E Campus Dr, Columbia, MO 65211

Study details

Currently enrolling

What is being offered: Gilvetmab anti-PD-1 infusion every 2 weeks for up to 10 doses

Who may qualify: Confirmed cancer diagnosis required

May not qualify if: Current steroids; Immunosuppressive

Costs / coverage: 🟡 Partially funded. Gilvetmab is covered; owners pay rechecks, bloodwork and chest radiographs.

Contact: Missouri Oncology Clinical Trials Service — 573-882-7821; cvmclinicaltrials@missouri.edu

Official study / enrollment information →

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →

SBRT for canine primary pulmonary carcinoma

Tufts University Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting — official Tufts individual protocol

What is being offered: A single cytologically or histopathologically confirmed primary pulmonary carcinoma must measure more than 1 cm in its shortest diameter and have received no previous tumor treatment. Multiple pulmonary nodules consistent with metastasis, regional node metastasis and pulmonary carcinomatosis exclude. No other malignant tumor diagnosed outside the lung within 30 days; a prior non-carcinoma malignancy can be allowed in remission if expected median survival exceeds one year. Screening CBC, chemistry and abdominal ultrasound within 30 days; anesthesia and SBRT suitability require clinician assessment. This is a VRTOG multicenter protocol, but the page does not name the other participating institutions; only the verified Tufts enrollment site is listed. Distinct from the Tufts SABR trial for progressive lung metastases.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation; Min tumor cm exclusive: 1; Single primary pulmonary carcinoma

May not qualify if: Prior radiation; Regional lymph node metastasis; Pulmonary metastasis; Significant comorbidity; Prior target tumor treatment

Costs / coverage: Partially funded: up to $4,000 for anesthesia, radiation planning and SBRT; up to $1,000 may be available for follow-up chest radiographs. Owners pay pre-enrollment bloodwork, planning CT, diagnosis confirmation and hospitalization for complications.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu

Official study / enrollment information →